Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-03 for Demodex Blepharitis
NCT04784091Phase 3Completed
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Start
- Apr 2021
- Primary completion
- May 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lotilaner in Demodex blepharitis (DB), sponsored by Tarsus Pharmaceuticals, Inc.. Started Apr 2021; status: completed.
02
Drugs
lotilaner
03
Conditions
Demodex blepharitis (DB)
Beyond the preview
Go deeper on NCT04784091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04784091.